http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Pre-Open Stock Movers 02/10: (TLRY) (GMDA) (CMLF) Higher; (VNRX) (CPST) (XONE) Lower (more...)
-
After-Hours Stock Movers 02/09: (GNFT) (MODN) (USNA) Higher; (VNRX) (XONE) (LMB) Lower (more...)
-
Pre-Open Movers 07/16: (LCI) (DELL) (AA) Higher; (TCDA) (NCLH) (GENE) Lower (more...)
-
UPS (UPS) Announces Expedited Global Delivery of QIAGEN (QGEN) Coronavirus Testing Kits
-
Spok Appoints Christine Cournoyer to Board of Directors
-
UPDATE: Axalta (AXTA) Viewed as Most Likely Takeover Target in Survey of M&A Desks - Bloomberg
-
QIAGEN Concludes Strategic Alternatives Review; Decides to Focus on Stand-Alone Business Strategy to Drive Future Value Creation
-
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives
-
Qiagen (QGEN) sees Q3 preliminary total net sales growth of about 3%
-
Qiagen (QGEN) CEO and Chairman Peer M. Schatz to Step Down
-
QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
-
QIAGEN Reports Preliminary Q3 2019 Results and Announces Measures to Prioritize Resource Allocation
-
QIAGEN Announces CEO Leadership Transition
-
Illumina (ILMN), QIAGEN (QGEN) Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
-
Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
-
QIAGEN Announces Change in Global Sales Structure
-
QIAGEN reports full results for second quarter and first half of 2019
-
QIAGEN Reports Results for Second Quarter of 2019; Updates Full-Year 2019 Outlook Due to Decision to Restructure China NGS Partnership
-
QIAGEN’s QuantiFERON®-TB Passes Milestone of 60 Million Tests in Global Fight against Tuberculosis, Current Annual Run Rate Exceeds 12 Million Tests
-
QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version
-
QIAGEN Highlights Profile of New QIAstat-Dx Meningitis / Encephalitis pAnel Focused on Most Prevalent Central Nervous System Pathogens
-
QIAGEN Reports Results for First Quarter 2018
-
QIAGEN and Natera partner to develop cutting-edge genetic testing assays for use on QIAGEN's GeneReader NGS System
-
QIAGEN Reports Results for Third Quarter and First Nine Months of 2017
-
QIAGEN Reports Results for Second Quarter and First Half of 2017
-
Bristol-Myers Squibb (BMY) & Qiagen (QGEN) Announce Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
-
Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
-
QIAGEN Reports Results for First Quarter 2017
-
QIAGEN Reports Results for Fourth Quarter and Full-year 2016
-
HTG Molecular Diagnostics (HTGM), QIAGEN (QGEN) Unit to Develop NGS-Based Diagnostics Solution
-
HTG Molecular Diagnostics and QIAGEN Team Up to Advance Precision Diagnostics
-
QIAGEN Reports Results for Third Quarter and First Nine Months of 2016
-
Qiagen (QGEN) Announces Launch of QIAscout
-
QIAGEN Launches QIAscout for Single-cell Isolation
-
QIAGEN Unveils Unique Sample to Insight Solutions for Liquid Biopsies and Hereditary Diseases
-
Pre-Open Stock Movers 10/11: (KMPH) (SUPN) (TWLO) Higher; (RCII) (ILMN) (LITE) Lower (more...)
-
QIAGEN Launches High-throughput Solutions for Human ID Databases
-
Qiagen (QGEN) Receives Unfavorable Decision in '537 Patent Suit
-
QIAGEN Comments on Preliminary Injunction and Confirms Intention to Defend its U.S. Intellectual Property Position
-
QIAGEN Welcomes U.S. Guidance for Latent TB Testing in Primary Care
-
Qiagen (QGEN) Plans to Return $250M to Shareholders Through Synthetic Buyback Program
-
QIAGEN Announces Plans to Return Approximately $250 Million to Shareholders Via Synthetic Share Repurchase Proposal
-
QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017
-
QIAGEN Launches "Digital NGS" Solutions with Unique Molecular Index Technology to Reliably Detect All Genetic Variation
-
QIAGEN Launches Novel Integrated System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-free DNA
-
Qiagen (QGEN) Completes Exiqon Tender Offer
-
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
-
QIAGEN Joins Consortium to Map Microbial Genomes in 54 Cities
-
QIAGEN Launches QIAsure Methylation Test to Determine Cervical Cancer Risk
-
Qiagen (QGEN) Reduces Offer Threshold for Acquisition of Exiqon A/S Shares

